Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study

1. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet 2021; 398: 1002–14. doi: 10.1016/S0140-6736(21)01206-X CarlinoMS LarkinJ LongGV Immune checkpoint inhibitors in melanoma Lancet 2021 398 1002 14 10.1016/S0140-6736(21)01206-X Open DOISearch in Google Scholar

2. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884–901. doi: 10.1093/annonc/mdz411 MichielinO van AkkooiACJ AsciertoPA DummerR KeilholzU ESMO Guidelines Committee Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2019 30 1884 901 10.1093/annonc/mdz411 Open DOISearch in Google Scholar

3. Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience. Radiol Oncol 2020; 54: 119–27. doi: 10.2478/raon-2020-0003 HribernikN BocM OcvirkJ Knez-ArbeiterJ MestiT IgnjatovicM Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience Radiol Oncol 2020 54 119 27 10.2478/raon-2020-0003 Open DOISearch in Google Scholar

4. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022; 40: 127–37. doi: 10.1200/JCO.21.02229 WolchokJD Chiarion-SileniV GonzalezR GrobJJ RutkowskiP LaoCD Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma J Clin Oncol 2022 40 127 37 10.1200/JCO.21.02229 Open DOISearch in Google Scholar

5. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6: 38. doi: 10.1038/s41572-020-0160-6 Ramos-CasalsM BrahmerJR CallahanMK Flores-ChávezA KeeganN KhamashtaMA Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 2020 6 38 10.1038/s41572-020-0160-6 Open DOISearch in Google Scholar

6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158–68. doi: 10.1056/NEJMra1703481 PostowMA SidlowR HellmannMD Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 2018 378 158 68 10.1056/NEJMra1703481 Open DOISearch in Google Scholar

7. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001 HaanenJ ObeidM SpainL CarbonnelF WangY RobertC ESMO Guidelines Committee Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2022 33 1217 38 10.1016/j.annonc.2022.10.001 Open DOISearch in Google Scholar

8. Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, et al. Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes. J Oncol Pract 2019; 15: e825–e834. doi: 10.1200/JOP.18.00703 BalajiA ZhangJ WillsB MarroneKA ElmariahH YarchoanM Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes J Oncol Pract 2019 15 e825 e834 10.1200/JOP.18.00703 Open DOISearch in Google Scholar

9. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323–41. doi: 10.1007/s00259-022-05780-2 LopciE HicksRJ Dimitrakopoulou-StraussA DercleL IravaniA SebanRD Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 Eur J Nucl Med Mol Imaging 2022 49 2323 41 10.1007/s00259-022-05780-2 Open DOISearch in Google Scholar

10. Iravani A, Hicks RJ. Imaging the cancer immune environment and Its response to pharmacologic intervention, Part 1: the role of ¹⁸F-FDG PET/CT. J Nucl Med 2020; 61: 943–50. doi: 10.2967/jnumed.119.234278 IravaniA HicksRJ Imaging the cancer immune environment and Its response to pharmacologic intervention, Part 1: the role of ¹⁸F-FDG PET/CT J Nucl Med 2020 61 943 50 10.2967/jnumed.119.234278 Open DOISearch in Google Scholar

11. Hribernik N, Huff DT, Studen A, Zevnik K, Klaneček Ž, Emamekhoo H, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging 2022; 49: 1857–69. doi: 10.1007/s00259-021-05650-3 HribernikN HuffDT StudenA ZevnikK KlanečekŽ EmamekhooH Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study Eur J Nucl Med Mol Imaging 2022 49 1857 69 10.1007/s00259-021-05650-3 Open DOISearch in Google Scholar

12. Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. PET/CT variants and pitfalls in malignant melanoma. Cancer Imaging 2022; 22: 3. doi: 10.1186/s40644-021-00440-4 AideN IravaniA PrigentK KottlerD AlipourR HicksRJ PET/CT variants and pitfalls in malignant melanoma Cancer Imaging 2022 22 3 10.1186/s40644-021-00440-4 Open DOISearch in Google Scholar

13. Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. ¹⁸F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 2020; 20: 36. doi: 10.1186/s40644-020-00313-2 WongA CallahanJ KeyaertsM NeynsB ManganaJ AberleS ¹⁸F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma Cancer Imaging 2020 20 36 10.1186/s40644-020-00313-2 Open DOISearch in Google Scholar

14. Huff DT, Ferjancic P, Namías M, Emamekhoo H, Perlman SB, Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis. Biomed Phys Eng Express 2021; 7: 10.1088/2057-1976/ac27c3. doi: 10.1088/2057-1976/ac27c3 HuffDT FerjancicP NamíasM EmamekhooH PerlmanSB JerajR Image intensity histograms as imaging biomarkers: application to immune-related colitis Biomed Phys Eng Express 2021 7 10.1088/2057-1976/ac27c3 10.1088/2057-1976/ac27c3 Open DOISearch in Google Scholar

15. Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of rresponse to immune checkpoint inhibitor therapy using early-time-point ¹⁸F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 2017; 58: 1421–8. doi: 10.2967/jnumed.116.188839 ChoSY LipsonEJ ImHJ RoweSP GonzalezEM BlackfordA Prediction of rresponse to immune checkpoint inhibitor therapy using early-time-point ¹⁸F-FDG PET/CT imaging in patients with advanced melanoma J Nucl Med 2017 58 1421 8 10.2967/jnumed.116.188839 Open DOISearch in Google Scholar

16. Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, et al. Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 2021; 48: 1932–43. doi: 10.1007/s00259-020-05137-7 SachpekidisC Kopp-SchneiderA PanL PapamichailD HaberkornU HasselJC Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma Eur J Nucl Med Mol Imaging 2021 48 1932 43 10.1007/s00259-020-05137-7 Open DOISearch in Google Scholar

17. Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, et al. FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Clin Cancer Res 2024; 24: OF1–OF10. doi: 10.1158/1078-0432.CCR-23-2390 AndersonTM ChangBH HuangAC XuX YoonD ShangCG FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma Clin Cancer Res 2024 24 OF1 OF10 10.1158/1078-0432.CCR-23-2390 Open DOISearch in Google Scholar

18. Taghanaki SA, Zheng Y, Kevin Zhou S, Georgescu B, Sharma P, Xu D, Comaniciu D, et al. Combo loss: Handling input and output imbalance in multi-organ segmentation. Comput Med Imaging Graph 2019; 75: 24–33. doi: 10.1016/j.compmedimag.2019.04.005 TaghanakiSA ZhengY Kevin ZhouS GeorgescuB SharmaP XuD ComaniciuD Combo loss: Handling input and output imbalance in multi-organ segmentation Comput Med Imaging Graph 2019 75 24 33 10.1016/j.compmedimag.2019.04.005 Open DOISearch in Google Scholar

19. Wang H, Zhang N, Huo L, Zhang B. Dual-modality multi-atlas segmentation of torso organs from [¹⁸F]FDG-PET/CT images. Int J Comput Assist Radiol Surg 2019; 14: 473–82. doi: 10.1007/s11548-018-1879-3 WangH ZhangN HuoL ZhangB Dual-modality multi-atlas segmentation of torso organs from [¹⁸F]FDG-PET/CT images Int J Comput Assist Radiol Surg 2019 14 473 82 10.1007/s11548-018-1879-3 Open DOISearch in Google Scholar

20. Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, et al. Hyperprogression and immunotherapy: Fact, fiction, or alternative fact? Trends Cancer 2020; 6: 181–91. doi: 10.1016/j.trecan.2020.01.005 AdashekJJ SubbiahIM MatosI GarraldaE MentaAK GaneshanDM Hyperprogression and immunotherapy: Fact, fiction, or alternative fact? Trends Cancer 2020 6 181 91 10.1016/j.trecan.2020.01.005 Open DOISearch in Google Scholar

21. National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.2021. [internet]. [cited 2023 Oct 23]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf National Cancer Institute (NCI) NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.2021. [internet] [cited 2023 Oct 23]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf Search in Google Scholar

22. Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, et al. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 2011; 12: 71. doi: 10.1186/1471-2105-12-71 NelsonEK PiehlerB EckelsJ RauchA BellewM HusseyP LabKey Server: an open source platform for scientific data integration, analysis and collaboration BMC Bioinformatics 2011 12 71 10.1186/1471-2105-12-71 Open DOISearch in Google Scholar

23. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021; 18: 203–11. doi: 10.1038/s41592-020-01008-z IsenseeF JaegerPF KohlSAA PetersenJ Maier-HeinKH nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation Nat Methods 2021 18 203 11 10.1038/s41592-020-01008-z Open DOISearch in Google Scholar

24. Baiocco S, Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Cittanti C, et al. SUV95th as a reliable alternative to SUVmax for determining renal uptake in [⁶⁸Ga] PSMA PET/CT. Mol Imaging Biol 2020; 22: 1070–7. doi: 10.1007/s11307-019-01451-1 BaioccoS MatteucciF MezzengaE CaroliP Di IorioV CittantiC SUV95th as a reliable alternative to SUVmax for determining renal uptake in [⁶⁸Ga] PSMA PET/CT Mol Imaging Biol 2020 22 1070 7 10.1007/s11307-019-01451-1 Open DOISearch in Google Scholar

25. Olsson-Brown A, Lord R, Sacco J, Wagg J, Coles M, Pirmohamed M. Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocr Connect 2020; 9: 318–25. doi: 10.1530/EC-19-0473 Olsson-BrownA LordR SaccoJ WaggJ ColesM PirmohamedM Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction Endocr Connect 2020 9 318 25 10.1530/EC-19-0473 Open DOISearch in Google Scholar

26. Nadaraja S, Helsing J, Naghavi-Bezhad M, Land LH, Ruhlmann CH, Gerke O, et al. Value of 2-[¹⁸F] FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. Clin Transl Imaging 2024; 12: 187–95. doi: 10.1007/s40336-024-00618-3 NadarajaS HelsingJ Naghavi-BezhadM LandLH RuhlmannCH GerkeO Value of 2-[¹⁸F] FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review Clin Transl Imaging 2024 12 187 95 10.1007/s40336-024-00618-3 Open DOISearch in Google Scholar

27. Gideonse BM, Birkeland M, Vilstrup MH, Grupe P, Naghavi-Behzad M, Ruhlmann CH, et al. Organ-specific accuracy of [¹⁸F] FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor. Jpn J Radiol 2024; 42: 753–64. doi: 10.1007/s11604-024-01554-y GideonseBM BirkelandM VilstrupMH GrupeP Naghavi-BehzadM RuhlmannCH Organ-specific accuracy of [¹⁸F] FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor Jpn J Radiol 2024 42 753 64 10.1007/s11604-024-01554-y Open DOISearch in Google Scholar

28. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323–41. doi: 10.1007/s00259-022-05780-2 LopciE HicksRJ Dimitrakopoulou-StraussA DercleL IravaniA SebanRD Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 Eur J Nucl Med Mol Imaging 2022 49 2323 41 10.1007/s00259-022-05780-2 Open DOISearch in Google Scholar

29. Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, et al. Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment. Cancers 2022; 29: 2687. doi: 10.3390/cancers14112687 ChiengJHL HtetZW ZhaoJJ TaiES TaySH HuangY Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment Cancers 2022 29 2687 10.3390/cancers14112687 Open DOISearch in Google Scholar

30. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563–80. doi: 10.1038/s41571-019-0218-0 MartinsF SofiyaL SykiotisGP LamineF MaillardM FragaM Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 2019 16 563 80 10.1038/s41571-019-0218-0 Open DOISearch in Google Scholar

31. Pan EY, Merl MY, Lin K. The impact of corticosteroid use during anti-PD1 treatment. J Oncol Pharm Pract 2020; 26: 814–22. doi: 10.1177/1078155219872786 PanEY MerlMY LinK The impact of corticosteroid use during anti-PD1 treatment J Oncol Pharm Pract 2020 26 814 22 10.1177/1078155219872786 Open DOISearch in Google Scholar

32. Hamidizadeh R, Eftekhari A, Wiley EA, Wilson D, Alden T, Bénard F. Metformin discontinuation prior to FDG PET/CT: A randomized controlled study to compare 24- and 48-hour bowel activity. Radiology 2018; 289: 418–25. doi: 10.1148/radiol.2018180078 HamidizadehR EftekhariA WileyEA WilsonD AldenT BénardF Metformin discontinuation prior to FDG PET/CT: A randomized controlled study to compare 24- and 48-hour bowel activity Radiology 2018 289 418 25 10.1148/radiol.2018180078 Open DOISearch in Google Scholar

33. Moasses-Ghafari B, Fallahi B, Esfehani AF, Eftekhari M, Rahmani K, Eftekhari A, et al. Effect of diet on physiologic bowel ¹⁸F-FDG uptake. J Nucl Med Technol 2021; 49: 241–5. doi: 10.2967/jnmt.120.257857 Moasses-GhafariB FallahiB EsfehaniAF EftekhariM RahmaniK EftekhariA Effect of diet on physiologic bowel ¹⁸F-FDG uptake J Nucl Med Technol 2021 49 241 5 10.2967/jnmt.120.257857 Open DOISearch in Google Scholar

34. Kang JY, Kim HN, Chang Y, Yun Y, Ryu S, Shin H, et al. Gut microbiota and physiologic bowel ¹⁸F-FDG uptake. EJNMMI Res 2017; 7: 72. doi: 10.1186/s13550-017-0318-8 KangJY KimHN ChangY YunY RyuS ShinH Gut microbiota and physiologic bowel ¹⁸F-FDG uptake EJNMMI Res 2017 7 72 10.1186/s13550-017-0318-8 Open DOISearch in Google Scholar

35. Strašek K, Huff DT, Hribernik H, Santoro Fernandey VMA, Vincent T., Klaneček Ž, et al. Assessing the impact of CNN architectures for whole organ segmentation on predictive models of organ toxicity. [abstract]. APS March Meeting 2024. March 4–8, 2024; Minneapolis & Virtual. Bulletin of the American Physical Society 2024. Abstract Z18.00003 StrašekK HuffDT HribernikH Santoro FernandeyVMA VincentT. KlanečekŽ Assessing the impact of CNN architectures for whole organ segmentation on predictive models of organ toxicity. [abstract] APS March Meeting 2024 March 4–8, 2024 Minneapolis & Virtual Bulletin of the American Physical Society 2024. Abstract Z18.00003 Search in Google Scholar